治疗慢性淋巴细胞白血病的新型药物 - Suppr

Suppr

超能文献

New Agents to Treat Chronic Lymphocytic Leukemia.

作者信息

Zaman Farasat, Savendahl Lars

机构信息

Karolinska Institutet, Stockholm, Sweden

出版信息

N Engl J Med. 2016 Jun 2;374(22):2185. doi: 10.1056/NEJMc1602674.

DOI:10.1056/NEJMc1602674

PMID:27248632

Abstract

摘要

相似文献

New Agents to Treat Chronic Lymphocytic Leukemia.

N Engl J Med. 2016 Jun 2;374(22):2185. doi: 10.1056/NEJMc1602674.

New Agents to Treat Chronic Lymphocytic Leukemia.

N Engl J Med. 2016 Jun 2;374(22):2186-7. doi: 10.1056/NEJMc1602674.

Venetoclax targets BCL2 in chronic lymphocytic leukaemia.

Lancet Oncol. 2016 Jan;17(1):e11. doi: 10.1016/S1470-2045(15)00576-8. Epub 2015 Dec 11.

Progress in Chronic Lymphocytic Leukemia with Targeted Therapy.

N Engl J Med. 2016 Jan 28;374(4):386-8. doi: 10.1056/NEJMe1515235.

Venetoclax (Venclexta) for chronic lymphocytic leukemia.

Med Lett Drugs Ther. 2016 Aug 1;58(1500):101-2.

Venetoclax: Bcl-2 inhibition for the treatment of chronic lymphocytic leukemia.

Drugs Today (Barc). 2016 Apr;52(4):249-60. doi: 10.1358/dot.2016.52.4.2470954.

ABT-199 for chronic lymphocytic leukemia.

Clin Adv Hematol Oncol. 2014 Oct;12(10):698-700.

Venetoclax in the treatment of chronic lymphocytic leukemia.

Expert Opin Drug Metab Toxicol. 2019 May;15(5):353-366. doi: 10.1080/17425255.2019.1606211. Epub 2019 Apr 25.

Suzanne Cory: Life-and-Death Switches: the Rise of BH3 Mimetics.

Trends Cancer. 2016 Oct;2(10):537-539. doi: 10.1016/j.trecan.2016.09.009. Epub 2016 Oct 13.

Venetoclax, the first BCL-2 inhibitor for use in patients with chronic lymphocytic leukemia.

Clin Adv Hematol Oncol. 2019 Aug;17(8):440-443.

引用本文的文献

A unique amphiphilic triblock copolymer, nontoxic to human blood and potential supramolecular drug delivery system for dexamethasone.

Sci Rep. 2021 Nov 2;11(1):21507. doi: 10.1038/s41598-021-00871-w.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

相似文献

New Agents to Treat Chronic Lymphocytic Leukemia.

N Engl J Med. 2016 Jun 2;374(22):2185. doi: 10.1056/NEJMc1602674.

New Agents to Treat Chronic Lymphocytic Leukemia.

N Engl J Med. 2016 Jun 2;374(22):2186-7. doi: 10.1056/NEJMc1602674.

Venetoclax targets BCL2 in chronic lymphocytic leukaemia.

Lancet Oncol. 2016 Jan;17(1):e11. doi: 10.1016/S1470-2045(15)00576-8. Epub 2015 Dec 11.

Progress in Chronic Lymphocytic Leukemia with Targeted Therapy.

N Engl J Med. 2016 Jan 28;374(4):386-8. doi: 10.1056/NEJMe1515235.

Venetoclax (Venclexta) for chronic lymphocytic leukemia.

Med Lett Drugs Ther. 2016 Aug 1;58(1500):101-2.

Venetoclax: Bcl-2 inhibition for the treatment of chronic lymphocytic leukemia.

Drugs Today (Barc). 2016 Apr;52(4):249-60. doi: 10.1358/dot.2016.52.4.2470954.

ABT-199 for chronic lymphocytic leukemia.

Clin Adv Hematol Oncol. 2014 Oct;12(10):698-700.

Venetoclax in the treatment of chronic lymphocytic leukemia.

Expert Opin Drug Metab Toxicol. 2019 May;15(5):353-366. doi: 10.1080/17425255.2019.1606211. Epub 2019 Apr 25.

Suzanne Cory: Life-and-Death Switches: the Rise of BH3 Mimetics.

Trends Cancer. 2016 Oct;2(10):537-539. doi: 10.1016/j.trecan.2016.09.009. Epub 2016 Oct 13.

Venetoclax, the first BCL-2 inhibitor for use in patients with chronic lymphocytic leukemia.

Clin Adv Hematol Oncol. 2019 Aug;17(8):440-443.

引用本文的文献

A unique amphiphilic triblock copolymer, nontoxic to human blood and potential supramolecular drug delivery system for dexamethasone.

Sci Rep. 2021 Nov 2;11(1):21507. doi: 10.1038/s41598-021-00871-w.